Skip to content
StockMarketAgent
Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

NBTX stock hub

Nanobiotix S.A. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

NBTXis not in this month’s coverageGet our monthly research letter — no spam
Fair value midpoint
n/a
Fair value pending
Upside to midpoint
n/a
Based on latest report
Confidence
n/a
Data quality and model convergence
Market cap
2.1B
NASDAQ
Market data

Live price

Current market quote for this ticker.

Current price
NBTX
In the news

Latest news · NBTX

Recent company headlines from major financial publishers.

Loading
—
Fetching the latest headlines.
Loading
—
Fetching the latest headlines.
Loading
—
Fetching the latest headlines.
Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming
DateLoading
Window—
EPS estimate—
Revenue estimate—
Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E9,904.2
P25 12.3P50 18.4P75 33.1
Trailing P/En/a
P25 14.9P50 23.2P75 38.5
ROEn/a
P25 -105.6P50 -46.5P75 -3.1
ROICn/a
P25 -63.1P50 -27.3P75 0.5
Benchmarks - 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a
Indicator catalog

All NBTX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields
196
Groups with data
11
Currency
EUR
Showing 196 of 196 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

25
MetricValue
Cik
0001760854
Company name
Nanobiotix S.A.
Country
France
Country code
US
Cusip
63009J107
Employees
103
Employees Change
-5%
Employees Change Percent
-4.63
Enterprise value
$2.2B
Exchange
NASDAQ
Financial currency
EUR
First seen
2026-05-09
Industry
Biotechnology
IPO Date
2020-12-11
Isin
US63009J1079
Last refreshed
2026-05-10
Market cap
$2.1B
Market cap category
Mid-Cap
Price
$45.49
Price currency
USD
Rev Per Employee
371,535.63x
Sector
Healthcare
Sic
2834
Symbol
NBTX
Website
https://www.nanobiotix.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

7
MetricValue
Earnings Yield
-1.34%
EV Sales Forward
18.16x
EV/Sales
56.35x
FCF yield
-1.9%
Forward P/E
9,904.16x
P/S ratio
55.04x
PS Forward
17.74x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

15
MetricValue
EBIT Margin
-33.39%
EBITDA Margin
-32.18%
Gross margin
100%
Gross Profit
$38.3M
Gross Profit Growth Q
-81.91%
Gross Profit Growth3 Y
89.68%
Gross Profit Growth5 Y
69.57%
Net Income
$-28.1M
Net Income Growth Years
1%
Pretax Margin
-73.51%
Profit Margin
-73.52%
Profit Per Employee
$-273,137
ROA
-10.06
Roa5y
-28.61
ROCE
-106.1

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

7
MetricValue
Cagr1y
1,280.96%
Cagr3y
89.52%
Cagr5y
24.75%
EPS Growth Years
1
Revenue Growth Years
1x
Revenue Growth3 Y
89.68x
Revenue Growth5 Y
69.57x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

16
MetricValue
Asset Turnover
$0.48
Assets
$79.6M
Cash
$61.9M
Current Assets
$74M
Current Liabilities
$67.8M
Debt
$111.9M
Equity
$-99.2M
Interest Coverage
-1.05
Liabilities
$178.8M
Long Term Assets
$5.6M
Long Term Liabilities
$110.9M
Net Cash
$-50M
Net Cash By Market Cap
$-2.37
Tangible Book Value
$-99.2M
Tangible Book Value Per Share
$-2.05
WACC
7.49

Liquidity

Current-asset coverage and working-capital efficiency metrics.

5
MetricValue
Current ratio
1.09
Net Working Capital
$-50.7M
Quick ratio
1.05
Working Capital
$6.2M
Working Capital Turnover
$1.79

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

2
MetricValue
Buyback Yield
-1.17%
Dividend Yield
0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

35
MetricValue
1Y total return
1,278.49%
200-day SMA
21.87
3Y total return
580.99%
50-day SMA
33.12
50-day SMA vs 200-day SMA
50over200
5Y total return
202.06%
All Time High
45.6
All Time High Change
-0.23%
All Time High Date
2026-05-08
All Time Low
1.75
All Time Low Change
2,499.43%
All Time Low Date
2023-05-01
ATR
2.84
Beta
0.58
Ch YTD
96.76
High
45.6
High52
45.6
High52 Date
2026-05-08
High52ch
-0.24%
Low
40.68
Low52
3.26
Low52 Date
2025-05-08
Low52ch
1,295.4%
Ma50ch
37.33%
Price vs 200-day SMA
107.96%
RSI
72.6
RSI Monthly
89.07
RSI Weekly
81.66
Sharpe ratio
2.88x
Sortino ratio
5.19
Total Return
-1.17%
Tr YTD
96.76
Tr1m
50.93%
Tr1w
29.53%
Tr3m
118.18%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

12
MetricValue
Analyst Count
2
Analyst Count Top
1
Analyst Price Target Top
$36
Analyst Ratings
Buy
Analyst Ratings Top
Strong Buy
Earnings Revenue Estimate
165,540,000x
Earnings Revenue Estimate Growth
1,164.15x
Operating Income
$-12.8M
Operating margin
-33.39
Price target
$33
Price Target Change
$-27.46
Price Target Change Top
$-20.86

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

11
MetricValue
Float
31,135,572%
Float Percent
64.35%
Net Borrowing
45,036,216.2
Shares Insiders
3.28%
Shares Institutions
12.02%
Shares Out
48,387,950
Shares Qo Q
1.69%
Shares Yo Y
1.17%
Short Float
0.04%
Short Ratio
0.16
Short Shares
0.02

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

61
MetricValue
Adjusted FCF
$-44.2M
Average Volume
86,110.4x
Bv Per Share
-2.05
CAPEX
$-631,678
Ch1m
50.93
Ch1w
29.53
Ch1y
1,278.5
Ch3m
118.2
Ch3y
581
Ch5y
202.1
Ch6m
128.9
Change
6.76%
Change From Open
10.95
Close
42.61
Days Gap
-3.78
Depreciation Amortization
463,464.2
Dollar Volume
2,574,597.5
Earnings Date
2026-03-31
Earnings Time
amc
EBIT
$-12.8M
EBITDA
$-12.3M
EPS
$-0.59
F Score
1
FCF
$-40M
FCF EV Yield
-1.86x
FCF Per Share
$-0.83
Financing CF
43,930,962
Fiscal Year End
December
Founded
2,003
Income Tax
$3,522
Investing CF
-678,643
Ipr
237
Iprfo
150.6
Is Primary Listing
0
Is Spac
No
Last Earnings Date
2026-03-31
Last Report Date
2025-12-31
Last Split Type
Never
Last10k Filing Date
2026-03-31
Ma150
25.85
Ma150ch
75.98%
Ma20
34.52
Ma20ch
31.79%
Net CF
3,538,805
Next Earnings Date
2026-09-17
Open
41
Optionable
No
Position In Range
97.76
Post Close
45.49
Postmarket Change Percent
1.14
Postmarket Price
$46.01
Ppne
4,917,673.2
Price Date
2026-05-08
Relative Volume
0.66x
Revenue
38,268,170x
SBC By Revenue
10.86x
Share Based Comp
4,155,219
Tax By Revenue
0.01x
Tr6m
128.94%
Volume
56,597
Z Score
1.11
Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate
n/a
Named kill scenarios are reviewed before any bullish rating can stand.
Moat score
n/a
Business quality stays separate from stock attractiveness.
Forward P/E
n/a
Valuation uses the full report model stack, not a single multiple.
Next action
Research pending
Final action steps are kept in the recommendation tab.
Income

Does NBTX pay a dividend?

Capital-return profile for this ticker.

Performance

NBTX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

1Y total return
+1278.5%
S&P 500 1Y: n/a
3Y total return
+581.0%
S&P 500 3Y: n/a
5Y total return
+202.1%
S&P 500 5Y: n/a
10Y total return
n/a
S&P 500 10Y: n/a
Ownership

Who owns NBTX?

Insider, institutional, and short-interest positioning.

Institutional ownership
+12.0%
Float: +64.3% of shares outstanding
Insider ownership
+3.3%
Stake held by company insiders. Higher generally signals alignment.
Short interest
+0.0%
0.2 days to cover
Y/Y dilution
+1.2%
Negative means the company is buying back shares.
Technical

NBTX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)
72.6
Above 70: short-term overbought
Price vs 200-day MA
+108.0%
50/200-day relationship not available
Beta (5Y)
0.58
Less volatile than the market
Sharpe ratio
2.88
Risk-adjusted return — higher is better; >1.0 is solid.
Questions

About NBTX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current NBTX stock rating?

Nanobiotix S.A. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full NBTX analysis?

The full report lives at /stocks/NBTX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for NBTX?

The latest report frames NBTX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the NBTX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.